PDCD1 and cancer: Cortellini and colleagues reported that among cancer patients subjected to PD‐1/PD‐L1 checkpoint inhibitors, obesity was the only clinically significant factor associated with grade 3–4 IRAEs and IRAEs prompting cessation of treatment [8].